Cornelie D. Andela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cornelie D. Andela has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Nienke R. Biermasz
Department of Medicine, Division of Endocrinology, and Center for Endocrine Tumors Leiden, Leiden University Medical Center, Leiden, the Netherlands
6 shared publications - Wouter Ralph van Furth
Department of Neurosurgery, University Neurosurgical Center Holland, Leiden University Medical Center , Leiden, ZA 2333
5 shared publications - Alberto Martin Pereira
Department of Endocrinology and Metabolism, Amsterdam University Medical Center, Amsterdam, the Netherlands
4 shared publications - Amir H. Zamanipoor Najafadabadi
Department of Ophthalmology, Leiden University Medical Center , Leiden, ZA 2333
4 shared publications - Daniel J. Lobatto
Department of Medicine, Division of Endocrinology, Pituitary Center and Center for Endocrine Tumors, Leiden University Medical Center, Leiden, The Netherlands
3 shared publications - Iris Catharina Maria Pelsma
Leiden University Medical Center
3 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
The Dutch prolactinoma cohort studies: cross-sectional analysis of females focusing on the patient's perspective
Purpose: To assess the results of patient-reported outcome measures (PROMs) by disease activity in a national cohort of females with a prolactinoma. Methods: Females with prolactinoma included in the PRolaCT or ProlaC study were assessed cross-sectionally, comparing patients with active (prolactin above upper limit of normal [ULN]) and controlled (prolactin < ULN) disease. Disease and treatment characteristics were reported. Patients completed PROMs on symptoms (modified PRO-CTCAE), health-related quality of life (HR-QoL) (SF-36), anxiety and depressive symptoms (Hospital Anxiety and Depression Scale (HADS)), and disease burden (Leiden Bother and Needs Questionnaire for patients with Pituitary disease [LBNQ-Pituitary]). Results: A total of 450 females with a prolactinoma were included (active: n = 223, controlled: n = 227); most (97.0%) were treated with dopamine agonists (DAs). Fatigue was the most prevalent symptom in both patients with active and controlled disease (92.6%, and 86.4%, respectively) followed by concentration problems (79.0%, and 64.5%, respectively) (modified PRO-CTCAE, LBNQ-Pituitary). Anxiety and depressive symptoms were worse in patients with active compared to controlled disease (HADS-Anxiety: 8.0 ± 4.5 vs 6.4 ± 4.5 P < .001. HADS-Depression: 6.4 ± 5.0 vs 4.7 ± 4.4 P < .001). Disease burden was higher in patients with active compared to controlled disease (LBNQ-Pituitary: Total Bother 24.4 ± 22.9 vs 16.4 ± 17.9; P < .001). Conclusion: Females with a prolactinoma were most affected by fatigue and cognitive complaints. Although patients with active disease perceived more burden than patients with controlled disease, symptoms including fatigue and psychological and cognitive complaints were prevalent despite disease control. Therefore, improvement of treatment and rehabilitation strategies is needed.
- 13 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open AccessThe Dutch prolactinoma cohort studies: cross-sectional analysis of females focusing on the patient's perspective
Purpose: To assess the results of patient-reported outcome measures (PROMs) by disease activity in a national cohort of females with a prolactinoma. Methods: Females with prolactinoma included in the PRolaCT or ProlaC study were assessed cross-sectionally, comparing patients with active (prolactin above upper limit of normal [ULN]) and controlled (prolactin < ULN) disease. Disease and treatment characteristics were reported. Patients completed PROMs on symptoms (modified PRO-CTCAE), health-related quality of life (HR-QoL) (SF-36), anxiety and depressive symptoms (Hospital Anxiety and Depression Scale (HADS)), and disease burden (Leiden Bother and Needs Questionnaire for patients with Pituitary disease [LBNQ-Pituitary]). Results: A total of 450 females with a prolactinoma were included (active: n = 223, controlled: n = 227); most (97.0%) were treated with dopamine agonists (DAs). Fatigue was the most prevalent symptom in both patients with active and controlled disease (92.6%, and 86.4%, respectively) followed by concentration problems (79.0%, and 64.5%, respectively) (modified PRO-CTCAE, LBNQ-Pituitary). Anxiety and depressive symptoms were worse in patients with active compared to controlled disease (HADS-Anxiety: 8.0 ± 4.5 vs 6.4 ± 4.5 P < .001. HADS-Depression: 6.4 ± 5.0 vs 4.7 ± 4.4 P < .001). Disease burden was higher in patients with active compared to controlled disease (LBNQ-Pituitary: Total Bother 24.4 ± 22.9 vs 16.4 ± 17.9; P < .001). Conclusion: Females with a prolactinoma were most affected by fatigue and cognitive complaints. Although patients with active disease perceived more burden than patients with controlled disease, symptoms including fatigue and psychological and cognitive complaints were prevalent despite disease control. Therefore, improvement of treatment and rehabilitation strategies is needed.
- Open Access
- 13 June 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (1) , e9-e22
Subtle Cognitive Impairments and Psychological Complaints in Patients With Prolactinoma Despite Biochemical Control
Purpose: To assess cognitive functioning and psychological complaints in patients with biochemically controlled prolactinoma. Methods: Cross-sectional study comparing otherwise healthy patients treated for prolactinoma to age-, gender-, and education level-matched controls. The cognitive assessment included 8 tests assessing memory, verbal fluency, processing speed, selective attention, and executive functioning. Additionally, patients completed 7 validated questionnaires on psychological complaints. Generalized estimating equations were performed. P values <.050 were considered significant. Results: Sixty patients (controlled on dopamine agonists, n = 30; in surgical remission, n = 30), among whom 41 (68.3%) females, aged 42.3 ± 11.7 years, were compared to 60 matched controls. Patients scored significantly lower on assessments for verbal memory (fewer words on Verbal Learning Test of Rey: β = −1.8; 95% CI, −2.7 to −1.0), selective attention (fewer correct digits on Digit Deletion Test [β = −8.8; 95% CI, −16.2 to −0.2], longer time on Trial Making Test A [β = 5.2; 95% CI, 3.2 to 7.2]), and processing speed (fewer correct substitutions on Digit-Symbol Substitution Test: β = –4.2; 95% CI, −8.2 to −0.2). Furthermore, patients reported higher degrees of apathy (Apathy Scale: β = 2.4; 95% CI, 0.6 to 4.1), irritability (Irritability Scale: β = 2.2; 95% CI, 0.3 to 4.1), fatigue (Fatigue Severity Scale: β = 6.7; 95% CI, 2.7 to 10.8), and anxiety and depressive symptoms (Hospital Anxiety and Depression Scale, anxiety: β = 1.1; 95% CI, 0.1 to 2.1; depression: β = 1.7; 95% CI, 0.8 to 2.7). Tests assessing executive functioning and task switching were comparable in patients and matched controls. Conclusion: Compared to matched controls, patients with biochemically controlled prolactinoma showed subtle cognitive impairments (ie, memory, attention, and processing speed) and reported more psychological complaints. Physicians should be aware of these impairments and address them adequately.
- 13 June 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (1) , e9-e22
Open AccessSubtle Cognitive Impairments and Psychological Complaints in Patients With Prolactinoma Despite Biochemical Control
Purpose: To assess cognitive functioning and psychological complaints in patients with biochemically controlled prolactinoma. Methods: Cross-sectional study comparing otherwise healthy patients treated for prolactinoma to age-, gender-, and education level-matched controls. The cognitive assessment included 8 tests assessing memory, verbal fluency, processing speed, selective attention, and executive functioning. Additionally, patients completed 7 validated questionnaires on psychological complaints. Generalized estimating equations were performed. P values <.050 were considered significant. Results: Sixty patients (controlled on dopamine agonists, n = 30; in surgical remission, n = 30), among whom 41 (68.3%) females, aged 42.3 ± 11.7 years, were compared to 60 matched controls. Patients scored significantly lower on assessments for verbal memory (fewer words on Verbal Learning Test of Rey: β = −1.8; 95% CI, −2.7 to −1.0), selective attention (fewer correct digits on Digit Deletion Test [β = −8.8; 95% CI, −16.2 to −0.2], longer time on Trial Making Test A [β = 5.2; 95% CI, 3.2 to 7.2]), and processing speed (fewer correct substitutions on Digit-Symbol Substitution Test: β = –4.2; 95% CI, −8.2 to −0.2). Furthermore, patients reported higher degrees of apathy (Apathy Scale: β = 2.4; 95% CI, 0.6 to 4.1), irritability (Irritability Scale: β = 2.2; 95% CI, 0.3 to 4.1), fatigue (Fatigue Severity Scale: β = 6.7; 95% CI, 2.7 to 10.8), and anxiety and depressive symptoms (Hospital Anxiety and Depression Scale, anxiety: β = 1.1; 95% CI, 0.1 to 2.1; depression: β = 1.7; 95% CI, 0.8 to 2.7). Tests assessing executive functioning and task switching were comparable in patients and matched controls. Conclusion: Compared to matched controls, patients with biochemically controlled prolactinoma showed subtle cognitive impairments (ie, memory, attention, and processing speed) and reported more psychological complaints. Physicians should be aware of these impairments and address them adequately.
- Open Access
- 1 November 2024
- Published by Springer Nature in Pituitary
- Vol. 27 (6) , 824-836
Approach to the patient with controlled acromegaly and acromegalic arthropathy: clinical diagnosis and management
Following the description of an illustrative case of a 70-year-old female patient with longstanding active acromegaly and invalidating, progressive joint complaints, current insights regarding diagnosis, treatment, and long-term management of acromegalic arthropathy are summarized. Since clinical trials on this topic are lacking, the reported recommendations are based on extensive clinical and research experience with this clinical entity, and on established diagnostics and interventions in patients with other rheumatic diseases. The cornerstones of the management of acromegalic arthropathy remains normalization of growth hormone and insulin growth factor-1 levels. However, patients with severe or progressive acromegalic arthropathy require a multidisciplinary approach to determine adequate diagnostics and treatment options. Because of the high prevalence and invalidating character of acromegalic arthropathy, developing evidence-based effective prevention and treatment strategies, preferably by international collaboration within rare disease networks, e.g., Endo-ERN, is a clear unmet need.
- 1 November 2024
- Published by Springer Nature in Pituitary
- Vol. 27 (6) , 824-836
Open AccessApproach to the patient with controlled acromegaly and acromegalic arthropathy: clinical diagnosis and management
Following the description of an illustrative case of a 70-year-old female patient with longstanding active acromegaly and invalidating, progressive joint complaints, current insights regarding diagnosis, treatment, and long-term management of acromegalic arthropathy are summarized. Since clinical trials on this topic are lacking, the reported recommendations are based on extensive clinical and research experience with this clinical entity, and on established diagnostics and interventions in patients with other rheumatic diseases. The cornerstones of the management of acromegalic arthropathy remains normalization of growth hormone and insulin growth factor-1 levels. However, patients with severe or progressive acromegalic arthropathy require a multidisciplinary approach to determine adequate diagnostics and treatment options. Because of the high prevalence and invalidating character of acromegalic arthropathy, developing evidence-based effective prevention and treatment strategies, preferably by international collaboration within rare disease networks, e.g., Endo-ERN, is a clear unmet need.
- Open Access
- 6 October 2020
- Published by Springer Nature in Pituitary
- Vol. 24 (1) , 79-95
Healthcare utilization and costs among prolactinoma patients: a cross-sectional study and analysis of determinants
Purpose: Prolactinomas are the most prevalent functioning pituitary adenomas. They affect gonadal function as well as health-related quality of life (HRQoL). This study aimed to report healthcare utilization and costs, including their determinants, for prolactinoma patients. Methods: Cross-sectional study of 116 adult prolactinoma patients in chronic care in a Dutch tertiary referral center. Patients completed four validated questionnaires, assessing healthcare utilization and costs over the previous 12 months (Medical Consumption Questionnaire), disease bother and needs (Leiden Bother and Needs Questionnaire Pituitary), HRQoL (Short Form-36), and self-reported health status (EuroQol 5D). Regression analyses were used to assess associations between disease-related characteristics and healthcare utilization and costs. Results: Mean age was 52.0 years (SD 13.7) and median follow-up was 15.0 years (IQR 7.6–26.1). Patients visited the endocrinologist (86.2%), general practitioner (37.9%), and ophthalmologist (25.0%) most frequently. Psychological care was used by 12.9% of patients and 5% were admitted to hospital. Mean annual healthcare costs were €1928 (SD 3319), mainly for pituitary-specific medication (37.6% of total costs), hospitalization (19.4%) and specialist care (16.1%). Determinants for higher healthcare utilization and costs were greater disease bother and needs for support, lower HRQoL, elevated prolactin, and longer disease duration, while tumor size, hypopituitarism and adrenal insufficiency were not significantly associated with healthcare utilization and costs. Conclusion: Healthcare utilization and costs of prolactinoma patients are related to patient-reported HRQoL, bother by disease and needs for support. Therefore, addressing patients’ HRQoL and needs is a way forward to improve efficiency of care and patients’ health status.
- 6 October 2020
- Published by Springer Nature in Pituitary
- Vol. 24 (1) , 79-95
Open AccessHealthcare utilization and costs among prolactinoma patients: a cross-sectional study and analysis of determinants
Purpose: Prolactinomas are the most prevalent functioning pituitary adenomas. They affect gonadal function as well as health-related quality of life (HRQoL). This study aimed to report healthcare utilization and costs, including their determinants, for prolactinoma patients. Methods: Cross-sectional study of 116 adult prolactinoma patients in chronic care in a Dutch tertiary referral center. Patients completed four validated questionnaires, assessing healthcare utilization and costs over the previous 12 months (Medical Consumption Questionnaire), disease bother and needs (Leiden Bother and Needs Questionnaire Pituitary), HRQoL (Short Form-36), and self-reported health status (EuroQol 5D). Regression analyses were used to assess associations between disease-related characteristics and healthcare utilization and costs. Results: Mean age was 52.0 years (SD 13.7) and median follow-up was 15.0 years (IQR 7.6–26.1). Patients visited the endocrinologist (86.2%), general practitioner (37.9%), and ophthalmologist (25.0%) most frequently. Psychological care was used by 12.9% of patients and 5% were admitted to hospital. Mean annual healthcare costs were €1928 (SD 3319), mainly for pituitary-specific medication (37.6% of total costs), hospitalization (19.4%) and specialist care (16.1%). Determinants for higher healthcare utilization and costs were greater disease bother and needs for support, lower HRQoL, elevated prolactin, and longer disease duration, while tumor size, hypopituitarism and adrenal insufficiency were not significantly associated with healthcare utilization and costs. Conclusion: Healthcare utilization and costs of prolactinoma patients are related to patient-reported HRQoL, bother by disease and needs for support. Therefore, addressing patients’ HRQoL and needs is a way forward to improve efficiency of care and patients’ health status.
- Open Access
- 19 June 2020
- Published by Springer Nature in Endocrine
- Vol. 70 (1) , 123-133
SF-12 or SF-36 in pituitary disease? Toward concise and comprehensive patient-reported outcomes measurements
Purpose: Pituitary diseases severely affect patients’ health-related quality of life (HRQoL). The most frequently used generic HRQoL questionnaire is the Short Form-36 (SF-36). The shorter 12-item version (SF-12) can improve efficiency of patient monitoring. This study aimed to determine whether SF-12 can replace SF-36 in pituitary care. Methods: In a longitudinal cohort study (August 2016 to December 2018) among 103 endoscopically operated adult pituitary tumor patients, physical and mental component scores (PCS and MCS) of SF-36 and SF-12 were measured preoperatively, and 6 weeks and 6 months postoperatively. Chronic care was assessed with a cross-sectional study (N = 431). Mean differences and agreement between SF-36 and SF-12 change in scores (preoperative vs. 6 months) were assessed with intraclass correlation coefficients (ICC) and limits of agreement, depicting 95% of individual patients. Results: In the longitudinal study, mean differences between change in SF-36 and SF-12 scores were 1.4 (PCS) and 0.4 (MCS) with fair agreement for PCS (ICC = 0.546) and substantial agreement for MCS (ICC = 0.931). For 95% of individual patients, the difference between change in SF-36 and SF-12 scores varied between −14.0 and 16.9 for PCS and between −7.8 and 8.7 for MCS. Cross-sectional results showed fair agreement for PCS (ICC = 0.597) and substantial agreement for MCS (ICC = 0.943). Conclusions: On a group level, SF-12 can reliably reproduce MCS in pituitary patients, although PCS is less well correlated. However, individual differences between SF-36 and SF-12 can be large. For pituitary diseases, alternative strategies are needed for concise, but comprehensive patient-reported outcome measurement.
- 19 June 2020
- Published by Springer Nature in Endocrine
- Vol. 70 (1) , 123-133
Open AccessSF-12 or SF-36 in pituitary disease? Toward concise and comprehensive patient-reported outcomes measurements
Purpose: Pituitary diseases severely affect patients’ health-related quality of life (HRQoL). The most frequently used generic HRQoL questionnaire is the Short Form-36 (SF-36). The shorter 12-item version (SF-12) can improve efficiency of patient monitoring. This study aimed to determine whether SF-12 can replace SF-36 in pituitary care. Methods: In a longitudinal cohort study (August 2016 to December 2018) among 103 endoscopically operated adult pituitary tumor patients, physical and mental component scores (PCS and MCS) of SF-36 and SF-12 were measured preoperatively, and 6 weeks and 6 months postoperatively. Chronic care was assessed with a cross-sectional study (N = 431). Mean differences and agreement between SF-36 and SF-12 change in scores (preoperative vs. 6 months) were assessed with intraclass correlation coefficients (ICC) and limits of agreement, depicting 95% of individual patients. Results: In the longitudinal study, mean differences between change in SF-36 and SF-12 scores were 1.4 (PCS) and 0.4 (MCS) with fair agreement for PCS (ICC = 0.546) and substantial agreement for MCS (ICC = 0.931). For 95% of individual patients, the difference between change in SF-36 and SF-12 scores varied between −14.0 and 16.9 for PCS and between −7.8 and 8.7 for MCS. Cross-sectional results showed fair agreement for PCS (ICC = 0.597) and substantial agreement for MCS (ICC = 0.943). Conclusions: On a group level, SF-12 can reliably reproduce MCS in pituitary patients, although PCS is less well correlated. However, individual differences between SF-36 and SF-12 can be large. For pituitary diseases, alternative strategies are needed for concise, but comprehensive patient-reported outcome measurement.
- Open Access
- 1 October 2019
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 181 (4) , 375-387
Toward Value Based Health Care in pituitary surgery: application of a comprehensive outcome set in perioperative care
Objective: Although widely advocated, applying Value Based Health Care (VBHC) in clinical practice is challenging. This study describes VBHC-based perioperative outcomes for patients with pituitary tumors up to 6 months postoperatively. Methods: A total of 103 adult patients undergoing surgery were prospectively followed. Outcomes categorized according to the framework of VHBC included survival, degree of resection, endocrine remission, visual outcome (including self-perceived functioning), recovery of pituitary function, disease burden and health-related quality of life (HRQoL) at 6 months (Tier 1); time to recovery of disease burden, HRQoL, visual function (Tier 2); permanent hypopituitarism and accompanying hormone replacement (Tier 3). Generalized estimating equations (GEEs) analysis was performed to describe outcomes over time. Results: Regarding Tier 1, there was no mortality, 72 patients (70%) had a complete resection, 31 of 45 patients (69%) with functioning tumors were in remission, 7 (12%, with preoperative deficits) had recovery of pituitary function and 45 of 47 (96%) had visual improvement. Disease burden and HRQoL improved in 36–45% at 6 months; however, there were significant differences between tumor types. Regarding Tier 2: disease burden, HRQoL and visual functioning improved within 6 weeks after surgery; however, recovery varied widely among tumor types (fastest in prolactinoma and non-functioning adenoma patients). Regarding Tier 3, 52 patients (50%) had persisting (tumor and treatment-induced) hypopituitarism. Conclusions: Though challenging, outcomes of a surgical intervention for patients with pituitary tumors can be reflected through a VBHC-based comprehensive outcome set that can distinguish outcomes among different patient groups with respect to tumor type.
- 1 October 2019
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 181 (4) , 375-387
Open AccessToward Value Based Health Care in pituitary surgery: application of a comprehensive outcome set in perioperative care
Objective: Although widely advocated, applying Value Based Health Care (VBHC) in clinical practice is challenging. This study describes VBHC-based perioperative outcomes for patients with pituitary tumors up to 6 months postoperatively. Methods: A total of 103 adult patients undergoing surgery were prospectively followed. Outcomes categorized according to the framework of VHBC included survival, degree of resection, endocrine remission, visual outcome (including self-perceived functioning), recovery of pituitary function, disease burden and health-related quality of life (HRQoL) at 6 months (Tier 1); time to recovery of disease burden, HRQoL, visual function (Tier 2); permanent hypopituitarism and accompanying hormone replacement (Tier 3). Generalized estimating equations (GEEs) analysis was performed to describe outcomes over time. Results: Regarding Tier 1, there was no mortality, 72 patients (70%) had a complete resection, 31 of 45 patients (69%) with functioning tumors were in remission, 7 (12%, with preoperative deficits) had recovery of pituitary function and 45 of 47 (96%) had visual improvement. Disease burden and HRQoL improved in 36–45% at 6 months; however, there were significant differences between tumor types. Regarding Tier 2: disease burden, HRQoL and visual functioning improved within 6 weeks after surgery; however, recovery varied widely among tumor types (fastest in prolactinoma and non-functioning adenoma patients). Regarding Tier 3, 52 patients (50%) had persisting (tumor and treatment-induced) hypopituitarism. Conclusions: Though challenging, outcomes of a surgical intervention for patients with pituitary tumors can be reflected through a VBHC-based comprehensive outcome set that can distinguish outcomes among different patient groups with respect to tumor type.